Conclusions
1 evidence topic · 27 sources
Summary
- Regulatory status: varegacestat, an oral, once-daily gamma secretase inhibitor, is not approved. Immunome submitted a New Drug Application in April 2026 for “the treatment of adults with desmoid tumors”; the FDA accepted it in July 2026 and assigned a PDUFA target action date of April 28, 2027. The EMA validated a marketing authorization application in October 2026. The FDA granted orphan drug designation in November 2023 and Fast Track designation for progressing desmoid tumors.
- Disease and unmet need: desmoid tumor is a “rare and locally aggressive monoclonal, fibroblastic proliferation” with an estimated incidence of 3–5 cases per million person-years; a literature review identified no U.S. epidemiological study, and most U.S. population figures are company estimates (SpringWorks: 1,000 to 1,650 new diagnoses a year and 5,500 to 7,000 actively managed patients from market research; Immunome: 10-11,000 actively managed patients). SpringWorks states that desmoid tumors “typically have a limited impact on mortality”; up to 63% of patients experience chronic pain, and 100 of 439 participants (23%) had recurrence after complete gross resection. The Desmoid Tumor Working Group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking, and Immunome states that the uptake of OGSIVEO shows the potential for gamma secretase inhibitors to address unmet need.
- Efficacy in RINGSIDE Part B (156 participants randomized to varegacestat 1.2 mg once daily, n=79, or placebo, n=77; data cutoff October 7, 2025): progression-free survival events occurred in 7 varegacestat and 29 placebo participants, with median PFS not estimable and 24.9 months. The hazard ratio is 0.16 (95% CI 0.07, 0.38) in the ASCO 2026 abstract and 0.16 (95% CI 0.071, 0.375) in Immunome's topline release. The confirmed objective response rate was 44 of 79 (55.7%) versus 7 of 77 (9.1%) in the abstract, and 56% versus 9% in the topline release. The difference in worst pain intensity at Week 12 was -2.42.
- Safety in RINGSIDE Part B: adverse events occurred in 100% of varegacestat and 91% of placebo participants, grade 3/4 adverse events in 57% and 17%, and diarrhea in 82% and 27%. Adverse events led to dose reduction in 80% of varegacestat participants and to discontinuation in 20% (placebo: 7% in the abstract, 6% in the primary results poster). Ovarian toxicity occurred in 20 of 36 premenopausal women (56%) receiving varegacestat; the abstract reports resolution in 11 of 20 (55%), and the safety poster reports resolution in all 8 women off treatment with follow-up available.
- Evidence limitations: Part B results are available as a congress abstract, congress presentations and posters, and Immunome releases; the ClinicalTrials.gov record lists no posted results. The study was sponsored by Immunome and Ayala Pharmaceuticals, and the comparator was placebo; Immunome states that “no head-to-head clinical trial has been conducted” against nirogacestat. The RINGSIDE primary endpoint counted radiographic progression by blinded independent central review, while the DeFi primary endpoint for nirogacestat also counted clinical progression. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo at the October 7, 2025 cutoff, and the patient-reported outcome analyses beyond the alpha-controlled secondary pain endpoint are exploratory.
- Approved comparator: OGSIVEO (nirogacestat), 150 mg twice daily, was first approved in the United States in 2023 and by the European Commission in August 2025. In DeFi, dose reductions due to adverse events occurred in 42% of nirogacestat recipients and ovarian dysfunction in 27 of 36 women of childbearing potential (75%). Its U.S. WAC is $7,746.58 per 14-tablet package (SpringWorks Connecticut disclosure dated 01/05/2026), after $29,000 per 180-count bottle of 50 mg tablets at introduction. NICE TA1199 recommends nirogacestat under a commercial arrangement, reports that the company concluded an acceptable ICER would be around £35,000 per QALY gained, and does not report the exact estimates because of confidential discounts; the G-BA found a “Hint for a minor additional benefit”.
- Not yet known: Immunome has “no drugs approved for commercial sale”, and the report quotes no prescribing information, commercial dosage strength, price, or launch date for varegacestat. A bioequivalence study of capsule formulations (VAR-505) is recruiting. The report quotes no cost-effectiveness analysis or budget impact model of varegacestat.